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Compound Retention in Care and All-Cause Mortality 
Among Persons Living With Human Immunodeficiency 
Virus
Emma Sophia Kay,1,  D. Scott Batey,2 Andrew O. Westfall,2 Katerina Christopoulos,3 Stephen R. Cole,4 Elvin H. Geng,3 W. Christopher Mathews,6  
Richard D. Moore,5 and Michael J. Mugavero2
1University of Michigan, Ann Arbor, 2University of Alabama at Birmingham, 3University of California, San Francisco, 6University of California, San Diego, 4University of North Carolina at Chapel Hill, 
and 5Johns Hopkins University, Baltimore, Maryland
Background. To obtain optimal health outcomes, persons living with human immunodeficiency virus (HIV) must be retained 
in clinical care. We examined the relationships between 4 possible combinations of 2 separate retention measures (missed visits and 
the Institute of Medicine [IOM] indicator) and all-cause mortality.
Methods. The sample included 4162 antiretroviral therapy (ART)–naive patients who started ART between January 2000 and 
July 2010 at any of 5 US sites of the Center for AIDS Research Network of Integrated Clinical Systems. The independent variable of 
interest was retention, captured over the 12-month period after the initiation of ART. The study outcome, all-cause mortality 1 year 
after ART initiation, was determined by querying the Social Security Death Index or the National Death Index. We evaluated the 
associations of the 4 categories of retention with all-cause mortality, using the Cox proportional hazards models.
Results. Ten percent of patients did not meet retention standards for either measure (hazard ratio [HR], 2.26; 95% confidence 
interval [CI], 1.59–3.21). Patients retained by the IOM but not the missed-visits measure (42%) had a higher HR for mortality (1.72; 
95% CI, 1.33–2.21) than patients retained by both measures (41%). Patients retained by the missed-visits but not the IOM measure 
(6%) had the same mortality hazards as patients retained by both measures (HR, 1.01; 95% CI, .54–1.87).
Conclusions. Missed visits within the first 12 months of ART initiation are a major risk factor for subsequent death. Incorporating 
missed visits in clinical and public health retention and viral suppression programming is advised.
Key words. hazard ratio; HIV/AIDS; mortality hazards; retention in care.
It is established that, to attain and maintain optimal health 
outcomes, persons living with human immunodeficiency virus 
(HIV) (PLWH) must be retained in clinical care [1–3]. In fact, 
retention in care (henceforth, “retention”) is 1 of 5 key steps in 
the HIV care continuum. This is a framework used to represent 
HIV care as a progression from testing to linkage and retention 
in care, prescription of antiretroviral therapy (ART), and, as the 
ultimate goal of ART and the preeminent biomarker of treat-
ment success, viral suppression [4–6]. According to estimates 
from the Centers for Disease Control and Prevention (CDC), 
less than half (48%) of the 1.1 million PLWH in the United 
States were retained in care in 2014 [7]. This poses a health con-
cern for PLWH as well as for population-level health, because 
PLWH who do not regularly attend their primary healthcare 
appointments are less likely to adhere to ART and, subsequently, 
are at increased risk of detectable virema with associated ad-
verse health outcomes and increased sexual transmission risk 
[8]. Poor retention also has negative implications for clinics be-
cause the time slots and resources reserved for patients who did 
not attend their scheduled visits go unused [9].
Given that retention is crucial for personal and population 
health, it is paramount that this step in the HIV care continuum 
receives continued attention. The National HIV/AIDS Strategy 
(NHAS) seeks to increase the proportion of PLWH who are 
retained in care to 90% by 2020 [10]. To reach and maintain this 
ambitious national target, however, it is important that the re-
tention health quality indicator be systematically captured and 
recorded as an ongoing prognostic measure of health. To this 
end, the retention indicator adopted by the Institute of Medicine 
(IOM) is endorsed by the NHAS as the metric to monitor reten-
tion [11, 12]. Notably, previous research has demonstrated that 
there is no gold standard to measure retention and that being 
retained in care, according to various commonly used retention 
measures, is associated with viral suppression [13, 14].
We previously evaluated the relationship between missed 
(“no-show”) primary care visits and increased mortality risk 
and found that, even when patients were classified as retained 
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in care by the IOM indicator, those who missed ≥3 scheduled 
visits had a significantly higher risk of death than patients who 
did not miss any scheduled visits [14]. Yet, few studies have 
compared HIV retention indicators to each other, whether in 
isolation, used in combination, or sequentially. For instance, 
an analysis of 2811 PLWH in the Kaiser Permanente Northern 
California healthcare system found that patients with ≥1 missed 
visit in their first year after diagnosis had a 71% increased mor-
tality risk compared with patients who did not miss any visits in 
that first year [15]. 
A Brazilian-based study found that patients who were new 
to HIV care and who missed more than a single 6-month visit 
during their first 2 years of care had an increased risk of death 
compared with patients who attended ≥3 of these 6-month visits 
[16]. Finally, research conducted in Kenya found that patients 
who missed a scheduled visit during a 12-month period had >6 
times the risk of death of patients who did not miss any visits, 
and that mortality risk increased with the number of missed 
visits [17]. Although these studies help illustrate the link between 
missed visits and mortality risk, less is known about the clinical 
significance of retention on mortality when multiple retention 
measures are combined, which we call compound retention.
In the current study, we examined the relationship between 
the 4 possible combinations of all-cause mortality with 2 sepa-
rate retention measures, missed visits and the IOM indicator. 
We hypothesized that each of the 4 possible combined reten-
tion categories (Table 1) would, when contrasted, be differen-
tially associated with all-cause mortality. Our study aim was 
to examine the relationship between these retention measures 
captured over the 12-month period after ART initiation and all-
cause mortality at the end of this period.
METHODS
Sample
The sample consisted of 4162 ART-naive adult patients 
(≥18  years old) who initiated therapy between January 2000 
and July 2010 at any of 5 sites associated with the Center 
for AIDS Research Network of Integrated Clinical Systems 
(CNICS), including the University of Alabama at Birmingham, 
the University of Washington, the University of California at 
San Diego, the University of North Carolina at Chapel Hill, and 
Case Western Reserve University. CNICS is a multisite clinical 
cohort that includes 8 geographically diverse HIV clinical sites 
across the United States [18]. All CNICS sites maintain elec-
tronic health record systems, thereby creating a centralized 
high-quality clinical database that captures clinical data from 
over 32  000 PLWH across sites [19, 20]. Although these data 
were collected at a time when ART regimens were compara-
tively less advanced, they offer an instructive glimpse into HIV 
care attendance patterns and associated mortality hazards.
Because we examined all-cause mortality for patients who 
had been taking ART for 1 year, patients who died during the 
12 months after ART initiation (n = 224) were excluded be-
cause the observation window was incomplete. The study was 
approved by institutional review boards at all 5 participating 
sites.
Variables of Interest
The primary independent variable was retention. We used 2 
separate measures for retention captured over the 12-month 
period after patients’ initiation of ART. We used the IOM indi-
cator endorsed by the NHAS for our kept visits measure, which 
defines retention as having ≥2 kept (or attended) primary care 
visits separated by ≥90 days during a 12-month period [11, 21]. 
We use the terms kept visit and missed visit to indicate the that 
the former measure looks at attended scheduled HIV primary 
care visits only, and the latter is a function of missed scheduled 
HIV primary care visits only.
A primary care visit was defined as a visit that addresses routine 
medical care and is scheduled in advance; this does not include 
emergency or walk-in visits or specialty care appointments. In 
keeping with prior research [13, 14], for the missed-visits measure, 
patients who missed no scheduled primary care visits during the 
12-month observation window were considered retained, and 
patients who missed ≥1 visit during that period were not retained 
(visits that were cancelled by the patient or provider were omitted 
from this calculation). Patients who did not attend any scheduled 
visits during the study period were considered not retained by 
both measures. Sensitivity analyses were also conducted in which 
more liberal cutoffs of <2 and <3 missed (no-show) visits were 
used for dichotomization of retained according to the missed-
visits retention measure (Table 1).
The outcome of interest, all-cause mortality, is recorded for 
all CNICS patients. CNICS sites regularly confirm and update 
patient all-cause mortality information by querying the Social 
Security Death Index and National Death Index twice a year. 
This way, CNICS can systematically capture and record reported 
deaths that were not already included in CNICS patient records. 
Even patients lost to follow-up are included in these queries and, 
if needed, their patient records are updated accordingly [22].
Table 1. All-Cause Mortality by Cross-Tabulation of Retention Measures
Retention per IOM 
Measurea
Retained per  
Missed-Visits Measure  
(0 No-Shows)
Not Retained per Missed-
Visits Measure (≥1 
No-Show)
Retained All-cause mortality for 
patients retained by 
both measures
All-cause mortality for 
patients retained by 
IOM measure only
Not retained All-cause mortality for 
patients retained by 
missed-visits measure 
only
All-cause mortality for 
patients not retained by 
either measure
Abbreviation: IOM, Institute of Medicine.
aThe IOM measure defines retention as having ≥2 kept (attended) primary care visits 
separated by ≥90 days during a 12-month period.
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We also included the following clinical and sociodemographic 
measures as covariates based on characteristics associated with 
retention in the literature (eg, in [23]): CNICS site, age, race/
ethnicity, sex, HIV transmission risk group (men who have sex 
with men, intravenous drug user, or heterosexual), and CD4+ 
cell counts and viral load values collected at the initial primary 
care visit, before ART initiation.
Statistical Analysis
Descriptive statistics for independent and dependent variables 
including means, standard deviations (SDs), counts, and 
frequencies, were conducted. We used χ2 tests to assess the 
relationship between the 2 retention measures and to obtain 
frequencies and percentages for the number of patients who 
comprised each of the 4 possible categories generated by the 
cross-tabulation of the 2 retention measures. We then used Cox 
proportional hazards models to evaluate the association of the 
4 categories of retention with all-cause mortality while control-
ling for study covariates, which were measured at ART initia-
tion (to account for the fact that patients who are not retained 
during the 1-year period will probably not have values at the 
1-year mark). The time origin for the survival analyses was 
1 year after patients began ART, to accommodate comparison 
of retention measures. We right-censored patients administra-
tively on 31 July 2012. Patients were observed for a mean (SD) 
of 4.8 (3.3) years, with a median of 4.3, a minimum of 0, and a 
maximum of 11.8 years from 1 year after ART start until death 
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Figure 1. Kaplan–Meier survival curves for all-cause mortality among patients 
classified as retained or not retained 12  months after initiation of antiretroviral 
therapy according to Institute of Medicine (IOM) and missed-visits (no-show) 
indicators. (The IOM measure defines retention as having ≥2 kept [attended] pri-
mary care visits separated by ≥90 days during a 12-month period.) The number of 
patients at risk is shown above the x-axis. A, Retained defined as 0 no-shows. B, 
Retained defined as <3 no-shows. C, Retained defined as <2 no-shows.
Table 2. Selected Sample Characteristics
Characteristic Patients, No. (%)a (N = 4162)
Age, mean (SD), y 38.0 (10.2)
Sex  
 Male 3360 (80.7)
 Female 802 (19.2)
Race  
 Black 1533 (64.0)
 White 2227 (29.9)
 Other/unknown 402 (6.1)
Risk transmission groupb  
 MSM 2241 (55.1)
 Intravenous drug user 502 (12.4)
 Heterosexual 1323 (32.5)
Baseline plasma HIV RNAc  
 1000–10 000 copies/mL 559 (13.5)
 10 001–100 000 copies/mL 1725 (41.4)
 >100 000 copies/mL 1739 (41.8)
Baseline CD4+ T-lymphocyte countd  
 <50/µL 869 (20.9)
 50–199/µL 1027 (24.7)
 200–349/µL 1201 (28.9)
 350–500/µL 619 (14.9)
 >500/µL 342 (8.2)
Abbreviations: HIV, human immunodeficiency virus; MSM, men who have sex with men; 
SD, standard deviation.
aData represent no. (%) of patients unless otherwise specified. Percentages based on 
non-missing data only.
bData missing in 96 patients (2.3%).
cData missing in 139 patients (3.3%)
dData missing in 104 patients (2.5%).
4 • ofid • Kay et al
or administrative censor. The median of the upper quartile was 
7.3 years, and the median of the lower quartile was 2.0 years. For 
inclusion in the sample, patients had to have ≥1 year of poten-
tial time receiving ART.
We also examined all-cause mortality among patients classi-
fied as retained or not retained at 12 months after ART initia-
tion for both retention measures, using Kaplan–Meier survival 
curves (Figure 1). Each patient’s first year of data was used to 
determine retention in care; beyond that, an individual patient’s 
data were not used (except for date of death). All analyses were 
conducted using SAS software, version 9.3 [24]. A significance 
level (α) of P < .05 was used to define statistical significance in 
all models.
RESULTS
Most patients were male (80.7%), black (64.0%), and categorized 
in the “men who have sex with men” risk transmission group 
(55.1%), with a mean (SD) age of 38 years (10.2) years (Table 2). 
Most patients (83.2%) had viral loads >10 000 copies/mL and a 
CD4+ cell count <350/µL (74.5%) at baseline (at ART initiation).
In the first year of taking ART, approximately half of patients 
were categorized as either retained by both measures or not 
retained by both measures, as shown in the diagonal cross-
tabulations in Table 3. Nearly half (41%) of patients were 
retained by both measures, yet the same proportion (42%) were 
also retained by the IOM but not the missed-visits measure. In 
contrast, just 6% of patients were retained by the missed-visits 
but not the IOM measure.
When the hazard ratios (HRs) were generated by Cox pro-
portional hazards modeling (Table 4), a pattern of mortality 
hazards emerged. Specifically, patients who were retained by the 
IOM but not the missed-visits measure had the highest HR for 
mortality (1.72; 95% confidence interval [CI], 1.33–2.21) when 
compared with patients retained by both measures. Patients who 
were considered not retained by either measure similarly had 
elevated mortality hazards (HR, 2.26; 95% CI, 1.59–3.21). On 
the other hand, patients retained by the missed-visits measure 
but not the IOM measure had the same HR as patients retained 
by both measures (1.01; 95% CI, .54–1.87). Results of the sensi-
tivity analyses were complementary, with larger effect sizes for 
missed visits on mortality when more missed visits were needed 
to be considered not retained (Table 5).
DISCUSSION
The cross-tabulation of 2 commonly used measures of retention 
among ART initiators provides an instructive glimpse into the 
relative mortality hazards experienced by PLWH who are clas-
sified into 1 of 4 retention categories in their first year of taking 
ART. Being classified as not retained by 1 of the 2 measures had 
a significant association with all-cause mortality, but only when 
that measure was based on missed visits. In fact, patients who 
were retained by the missed-visits measure, but not the IOM 
measure, had approximately the same mortality hazards as 
those who were retained by both measures.
These findings contribute to the literature that suggests that 
missed visits are associated with increased risk of death [14–17]. 
As a recent multisite analysis found that the strongest predictor 
of future missed visits is prior missed visits [25]; even a single 
missed visit may be indicative of poor HIV care attendance, and 
consequently poor HIV health, in the long term. Our findings 
also provide additional understanding about the relationship 
between multiple categories of retention, designated as com-
pound retention in the current study, and all-cause mortality. 
Given that nearly half of the patients (42%) missed ≥1 visit 
during the 12 months after they started ART but were still clas-
sified as retained using the IOM kept visits measure, it is vital 
that clinicians make use of this missed-visits measure that is ad-
ministratively and computationally straightforward. Indeed, if 
this analysis had measured retention using the IOM measure 
alone, the increased mortality hazards associated with missed 
visits would not have been apparent.
Using cross-tabulation, we found that combinations of reten-
tion measures are associated with differential mortality hazards 
for PLWH after their first year of taking ART. Clinicians can 
apply this tool to their practices, thereby identifying patients 
Table 3. Cross-Tabulation of Institute of Medicine and Missed-Visits 
Retention Measuresa
Retention per 
IOM Measureb
Patients, No. (%)
Retained per Missed-Visits 
Measure (0 No-Shows)
Not Retained per 
Missed-Visits Measure 
(≥1 No-Show)
Retained 1725 (41) 1753 (42)
Not retained 251 (6) 433 (10)
Abbreviations: IOM, Institute of Medicine;
aCovariates include site, age, race/ethnicity, sex, human immunodeficiency virus transmis-
sion risk group, and pre–antiretroviral therapy CD4+ cell count and viral load.
bThe IOM measure defines retention as having ≥2 kept (attended) primary care visits 
separated by ≥90 days during a 12-month period.
Table 4. Hazard Ratios for All-Cause Mortality by Cross-Tabulation of 
Institute of Medicine and Missed-Visits Retention Measuresa
Retention per 
IOM Measureb
HR for All-Cause Mortality (95% CI)
Retained per Missed-Visits 
Measure (0 No-Shows)
Not Retained per 
Missed-Visits Measure 
(≥1No-Show)
Retained Referent 1.72c (1.33–2.21)
Not retained 1.01 (.54–1.87) 2.26c (1.59–3.21)
Abbreviations: CI, confidence interval; HR, hazard ratio; IOM, Institute of Medicine.
aCovariates include site, age, race/ethnicity, sex, human immunodeficiency virus transmis-
sion risk group, and pre–antiretroviral therapy CD4+ cell count and viral load.
bThe IOM measure defines retention as having ≥2 kept (attended) primary care visits 
separated by ≥90 days during a 12-month period.
cP < .001.
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at risk who would benefit from targeted interventions aimed at 
increasing retention (to include both an increase in attended 
visits and a decrease in missed visits). There is evidence that even 
short, motivational interviewing-based retention strategies, 
such as the single-session, 60-minute intervention recently de-
veloped by Smith and colleagues [26], may be effective, even in 
fast-paced clinic settings [27].
Importantly, as has been observed elsewhere, there is no ref-
erence standard to measure retention [13, 14]. Although the 
IOM indicator did not independently predict mortality hazards 
among ART initiators in this clinical cohort study, this measure 
has clear value. Beyond being associated with viral suppression 
[28], the IOM indicator can be captured from public health sur-
veillance data and used as a proxy for care visits, because viral 
load is routinely measured at HIV primary care visits. As such, it 
represents a benchmark and public health quality indicator, well 
served for application by the IOM and NHAS. Moreover, 2 visits 
over 12 months separated by ≥90 days, as captured by the IOM 
measure, may be considered a bare minimum of attended visits 
to constitute care retention. As increasing proportions of PLWH 
are being scheduled every 6 months, this measure still has clin-
ical validity and utility. However, as suggested by our findings, 
other complementary retention measures, such as missed visits, 
have added prognostic value and, in certain settings, like HIV 
clinics, can be a valuable adjuvant to the IOM indicator. In par-
ticular, the missed-visits retention measure is instructive as an 
immediately actionable indicator of mortality hazards.
This research has several limitations. Foremost, the present 
report is an observational study and there may be unmeasured 
causes of death that differ between persons classified as retained 
and those classified as not retained. Such potential differential 
assessments of these causes may cause confounding. Although 
our sample represented 5 different geographically diverse sites, 
the results may not be generalizable to all PLWH in the United 
States. Because the outcome of interest was all-cause mortality, 
we were unable to discern whether death was caused by AIDS-
related causes. Similarly, our outcome of interest, all-cause mor-
tality, was determined using the Social Security Death Index and 
National Death Index, which may not account for all deaths. We 
did not systematically capture whether patients transferred care 
during the 12 months after they began ART, although it is likely 
that the transfer rate was minimal during the short observa-
tion window. In addition, these results cannot be generalized to 
PLWH who receive ART outside an HIV clinic setting. Finally, 
this research did not capture trends in retention over time, be-
cause retention outcomes were assessed only for the first year 
after ART initiation. However, proximal retention in care—es-
pecially that based on missed visits—is a valuable indicator 
available to clinicians that may help prevent premature death.
In conclusion, these results indicate that patients starting 
ART who miss scheduled visits during the following 12-month 
period, even if they are considered retained by IOM and NHAS 
standards, have significantly higher risks of death than those 
who do not have any no-show visits. Although the missed-visits 
measure seems to carry more clinical value, we still recommend 
use of the IOM measure for 2 reasons. First, many clinics do not 
collect detailed data on missed visits and keep records only on 
attended visits. Second, the IOM measure is the only retention 
measure that, thus far, has received national endorsement (ie, 
National HIV/AIDS Strategy and IOM).
If we are to reach 90% retention among PLWH in the United 
States by 2020 [10], substantial strides must be made to keep 
patients retained in care. Increasing retention among PLWH 
has individual-level as well as public health implications, as 
recently seen in the “U  =  U” campaign, which highlights the 
fact that having a sustained undetectable viral load effectively 
prevents sexual transmission [29]. To this end, incorporating 
missed visits in clinical and public health retention and viral 
suppression programming is advised based on study findings.
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Table 5. Sensitivity Analysis for Hazard Ratios for All-Cause Mortality by Cross-Tabulation of Institute of Medicine and Missed-Visits Retention Measuresa
Retention per IOM  
Measureb
HR for All-Cause Mortality (95% CI)
Retained per Missed-Visits 
Measure (<2 No-Shows)
Not Retained per Missed-Visits Measure 
(≥2 No-Shows)
Retained per Missed-Visits 
Measure (<3 No-Shows)
Not Retained per 
Missed-Visits Measure 
(≥3 No-Shows)
Retained Referent 1.87c (1.45–2.42) Referent 2.12c (1.58–2.84)
Not retained 1.32 (.90–1.93) 2.40c (1.58–3.64) 1.35 (.97–1.87)  2.84c (1.67–4.84)
Abbreviations: CI, confidence interval; HR, hazard ratio; IOM, Institute of Medicine.
aCovariates include site, age, race/ethnicity, sex, human immunodeficiency virus transmission risk group, and pre–antiretroviral therapy CD4+ cell count and viral load.
bThe IOM measure defines retention as having ≥2 kept (attended) primary care visits separated by ≥90 days during a 12-month period.
cP < .001.
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